Teza Capital Management’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-11,098
| Closed | -$276K | – | 445 |
|
|
2025
Q1 | $276K | Sell |
11,098
-2,319
| -17% | -$57.6K | 0.13% | 277 |
|
|
2024
Q4 | $253K | Sell |
13,417
-2,172
| -14% | -$40.9K | 0.04% | 391 |
|
|
2024
Q3 | $235K | Buy |
15,589
+2,375
| +18% | +$35.7K | 0.03% | 522 |
|
|
2024
Q2 | $378K | Sell |
13,214
-5,741
| -30% | -$164K | 0.05% | 407 |
|
|
2024
Q1 | $554K | Buy |
18,955
+10,596
| +127% | +$310K | 0.07% | 326 |
|
|
2023
Q4 | $282K | Sell |
8,359
-2,140
| -20% | -$72.2K | 0.05% | 426 |
|
|
2023
Q3 | $322K | Buy |
10,499
+858
| +9% | +$26.3K | 0.05% | 416 |
|
|
2023
Q2 | $386K | Buy |
+9,641
| New | +$386K | 0.06% | 341 |
|
|
2020
Q3 | – | Sell |
-8,027
| Closed | -$421K | – | 547 |
|
|
2020
Q2 | $421K | Buy |
+8,027
| New | +$421K | 0.09% | 324 |
|
|
2018
Q4 | – | Sell |
-6,563
| Closed | -$323K | – | 447 |
|
|
2018
Q3 | $323K | Buy |
+6,563
| New | +$323K | 0.07% | 309 |
|